A*STAR’s Genome Institute of Singapore (GIS) scientists have discovered potential drug targets for triple-negative breast cancer (TNBC) using integrated genomic approaches.

The GIS scientists, in partnership with other research institutions, found that UBASH3B is a protein tyrosine phosphatase that plays a key role in the invasive growth of TNBC.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

According to their findings, UBASH3B is overexpressed in one third of TNBC patients and is responsible for regulating the activity of a key breast cancer gene.

"Being able to predict which patients are more likely to relapse is important since these patients may benefit from more aggressive treatments."

After conducting further studies in a mouse model, the researchers concluded that the growth of TNBC cell and lung metastasis can be reduced by deleting the gene expression.

GIS scientists also found that high levels of UBASH3B are directly proportional to early recurrence and metastasis in TNBC patients.

See Also:

Tan Tock Seng Hospital consultant surgeon and a collaborator and co-author of the study Dr Tan Ern Yu said that some TNBC patients relapse soon after standard treatment, while others remain free of disease for a long time.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Being able to predict which patients are more likely to relapse is important since these patients may benefit from more aggressive treatments," Tan Ern Yu said.

"Further validation will show whether UBASH3B can be developed into a means of identifying these high-risk patients, as well as a new form of treatment."